References of "Pirotte, Bernard"
     in
Bookmark and Share    
Peer Reviewed
See detailIdentification d’inhibiteurs sélectifs de la cyclooxygénase-2 (COX-2)
Michaux, C.; Julemont, F.; De Leval, X. et al

Conference (2004, June)

Detailed reference viewed: 14 (0 ULg)
Peer Reviewed
See detailIdentification d’un inhibiteur COX-2 sélectif », 18èmes Journées Franco-belges de Pharmacochimie
Michaux, C.; Julemont, F.; De Leval, X. et al

Poster (2004, June)

Detailed reference viewed: 8 (0 ULg)
Peer Reviewed
See detailSynthèse et évaluation pharmacologique d’analogues pyridiniques du nimésulide : variation du pont « inter-cycle
Julemont, F.; De Leval, X.; Dogne, J. M. et al

Poster (2004, June)

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailNew analogues of the potassium channel opener cromakalim: effects on rat pancreatic B-cells and rat aorta rings
Sebille, S.; De Tullio, Pascal ULg; Antoine, M. H. et al

Conference (2004, May)

Detailed reference viewed: 4 (0 ULg)
Peer Reviewed
See detailDevelopment of thromboxane A2 modulators as promising anti-metastatic and anti-angiogenic compounds
De Leval, X.; Dassesse, T.; Benoit, V. et al

Conference (2004, May)

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailNew developments on thromboxane modulators
Dogné, Jean-Michel ULg; Hanson, Julien ULg; De leval, X. et al

in Mini Reviews in Medicinal Chemistry (2004)

Detailed reference viewed: 19 (3 ULg)
Full Text
Peer Reviewed
See detailEffects of COX-2 inhibitors on ROS produced by Chlamydia pneumoniae-primed human promonocytic cells (THP-1)
Mouithys-Mickalad, Ange ULg; Deby, Ginette ULg; Dogné, Jean-Michel ULg et al

in Biochemical and Biophysical Research Communications (2004), 325(4), 1122-1130

Chronic inflammation through foam cells and macrophages is important in atherosclerosis development, and can be considered as therapeutic targets. Cyclooxygenase and NADPH-oxidase were expressed within ... [more ▼]

Chronic inflammation through foam cells and macrophages is important in atherosclerosis development, and can be considered as therapeutic targets. Cyclooxygenase and NADPH-oxidase were expressed within atherosclerotic lesions. Reactive oxygen species produced by NADPH oxidase were found to trigger the cyclooxygenase-2 expression. The effects of preferential COX-2 inhibitors on ROS produced by Chlamydia-primed human monocytes (THP-1 cells) were evaluated by fluorescence, chemiluminescence, oxymetry, and EPR spin trapping. Fluorescence assays showed an increased production of ROS with Chlamydia versus cells primed by 10(-8) M PMA. COX-2 inhibitors inhibited in a dose-dependent manner the luminol-enhanced CL while ibuprofen and diclofenac increased the chemiluminescence response. By EPR spin trapping, COX-2 inhibitors, ibuprofen, and diclofenac, exhibited a dose-dependent inhibiting effect (10 and 100 muM) on the EPR signal appearance. Our cell model combining EPR, chemiluminescence, and oxymetry appeared relevant to study the modulating effects of preferential COX-2 inhibitors on the cell oxidant activity and chronic inflammatory diseases. (C) 2004 Elsevier Inc. All rights reserved. [less ▲]

Detailed reference viewed: 128 (36 ULg)
Full Text
Peer Reviewed
See detailNew developments on thromboxane and prostacyclin modulators. Part II: prostacyclin modulators
De Leval, X.; Hanson, Julien ULg; David, Jean-Louis ULg et al

in Current Medicinal Chemistry (2004), 11

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailFirst and second generations of COX-2 selective inhibitors
De leval, X.; Julémont, F.; Benoit, V. et al

in Mini Reviews in Medicinal Chemistry (2004), 4

Detailed reference viewed: 25 (4 ULg)
Full Text
Peer Reviewed
See detailRecent developments in the chemistry of potassium channel activators : the cromakalim analogues
Sebille, S.; De Tullio, Pascal ULg; Boverie, S. et al

in Current Medicinal Chemistry (2004), 11

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailCharacterization of preferential activity on platelet thromboxane A2 receptors of BM-613, a new thromboxane A2 antagonist
Hanson, Julien ULg; Rolin, S.; De Leval, X. et al

in Fundamental & Clinical Pharmacology (2004)

Detailed reference viewed: 3 (1 ULg)
Full Text
Peer Reviewed
See detailNew developments on thromboxane and prostacyclin modulators. Part I: thromboxane modulators
Dogné, Jean-Michel ULg; De leval, X.; Hanson, Julien ULg et al

in Current Medicinal Chemistry (2004), 11

Detailed reference viewed: 22 (2 ULg)
Full Text
Peer Reviewed
See detailNew analogues of the KATP channel opener cromakalim : synthesis and pharmacological evaluation on rat pancreatic B-cells and rat aorta rings
Sebille, S.; De Tullio, Pascal ULg; Antoine, M. H. et al

in Fundamental & Clinical Pharmacology (2004)

Detailed reference viewed: 32 (4 ULg)
Full Text
Peer Reviewed
See detailNew trends in the development of positive allosteric modulators of AMPA receptors
Graindorge, E.; Francotte, Pierre ULg; Boverie, S. et al

in Current Medicinal Chemistry - Central Nervous System Agents (2004), 4

Detailed reference viewed: 7 (4 ULg)